<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antiarrhythmic drug therapy will continue to play an important role in the treatment of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) </plain></SENT>
<SENT sid="1" pm="."><plain>Pharmacological therapy is focused on AF symptom relief and on prevention of tachycardiomyopathy </plain></SENT>
<SENT sid="2" pm="."><plain>The choice between the various anti-arrhythmic drugs available, either for rate or rhythm control, mainly depends on the underlying <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e>, type of AF and possible side-effects </plain></SENT>
<SENT sid="3" pm="."><plain>New anti-arrhythmic drugs in the guidelines vernakalant and <z:chebi fb="0" ids="50659">dronedarone</z:chebi> are promising, but further research is required to explore their role in treatment of patients with AF </plain></SENT>
<SENT sid="4" pm="."><plain>In this review, we will discuss the role of antiarrhythmic drugs in management of patients with AF according to the new AF guidelines of the European Society of Cardiology </plain></SENT>
</text></document>